Aquestive Therapeutics (AQST) EBITDA (2017 - 2026)

Aquestive Therapeutics' EBITDA history runs 10 years deep, the most recent figure standing at -$4.2 million for Q1 2026.

• On a quarterly basis, EBITDA rose 78.29% year-over-year to -$4.2 million in Q1 2026; TTM through Mar 2026 was -$55.9 million, a 35.72% decrease from a year earlier, with the FY2025 full-year figure at -$71.1 million, down 130.9% from the prior year.
• EBITDA rose to -$4.2 million in Q1 2026 per AQST's latest filing, from -$28.8 million in the prior quarter.
• Across five years, EBITDA topped out at $55000.0 in Q2 2024 and bottomed at -$28.8 million in Q4 2025.
• The 5-year median for EBITDA is -$9.0 million (2024), against an average of -$9.6 million.
• Across the five-year window, EBITDA surged 101.31% in 2024 and slumped 20769.09% in 2025, its largest moves.
• Year by year, EBITDA stood at -$10.7 million in 2022, then soared by 63.49% to -$3.9 million in 2023, then tumbled by 247.2% to -$13.6 million in 2024, then plunged by 112.38% to -$28.8 million in 2025, then surged by 85.42% to -$4.2 million in 2026.
• Per Business Quant, the three latest AQST EBITDA figures stand at -$4.2 million (Q1 2026), -$28.8 million (Q4 2025), and -$11.5 million (Q3 2025).